Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for LabCorp (LH) is 8/10.
Revenue grew 5.8% to $3.5 billion with adjusted EPS of $4.25, up 10.6%, as specialty testing in neurology and oncology drove double-digit growth. The consumer health platform and AI-powered diagnostics launches expanded the addressable market while the CHOP collaboration was signed. Management raised full-year EPS guidance to $17.70-$18.35, upgrading the growth rate to approximately 10%.
Scored from LabCorp’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.
On August 11, 2026, Megan D. Bailey notified Labcorp of her decision to resign as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026. Effective September 1, 2026, Brian J. Caveney, M.D. will assume the role of Executive Vice President and President, Biopharma Laboratory Services, overseeing both the Early Development Research Laboratories and Central Laboratories businesses.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $3.33B | +9.8% | $1.70 | +186.3% | 26.9% | 6.5% | 4.3% | $665M |
| FY2025 Q1 | $3.35B | +5.3% | $2.52 | -6.3% | 28.3% | 9.7% | 6.4% | $-108M |
| FY2025 Q2 | $3.53B | +9.5% | $2.84 | +16.4% | 29.7% | 11.2% | 6.7% | $543M |
| FY2025 Q3 | $3.56B | +8.6% | $3.12 | +55.2% | 28.8% | 11.1% | 7.3% | $281M |
| FY2025 Q4 | $3.52B | +5.6% | $1.98 | +16.5% | 26.2% | 10.9% | 4.7% | $490M |
| FY2026 Q1 | $3.54B | +5.8% | $3.35 | +32.9% | 26.5% | 10.8% | 7.9% | $71M |
| FY2026 Q2 | $3.73B | +5.8% | $3.64 | +28.2% | 31.8% | 11.9% | 8.0% | $314M |